07:19 AM EDT, 06/14/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) has sued Corcept Therapeutics ( CORT ) , accusing the company of monopolizing the market for Korlym, a mifepristone-based drug used to treat Cushing's syndrome, according to the complaint filed with a federal court in San Francisco on Thursday.

The lawsuit claims that Corcept, in collaboration with Korlym's exclusive distributor Optime Care, has engaged in practices to prevent competition. Teva accused Corcept of allegedly paying bribes and kickbacks to physicians to ensure continued prescriptions of Korlym.

Teva alleges that Corcept and Optime Care have maintained a long-term exclusive-dealing arrangement that prevents Optime from distributing competing medications.

Teva and Corcept did not immediately respond to requests for comment from MT Newswires.

Price: 17.36, Change: -0.04, Percent Change: -0.23